Cumberland Pharmaceuticals Inc. (CPIX)
USD 3.91
(-4.87%)
USD 3.91
(-4.87%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 81.77 Million USD | -12.0% |
| 2022 | 92.92 Million USD | 10.02% |
| 2021 | 84.45 Million USD | -12.44% |
| 2020 | 96.46 Million USD | -7.73% |
| 2019 | 104.54 Million USD | -7.23% |
| 2018 | 112.69 Million USD | 20.87% |
| 2017 | 93.23 Million USD | -0.18% |
| 2016 | 93.4 Million USD | 1.62% |
| 2015 | 91.91 Million USD | -3.65% |
| 2014 | 95.4 Million USD | 8.89% |
| 2013 | 87.61 Million USD | -11.14% |
| 2012 | 98.59 Million USD | 3.22% |
| 2011 | 95.51 Million USD | 3.76% |
| 2010 | 92.05 Million USD | -11.25% |
| 2009 | 103.72 Million USD | 233.31% |
| 2008 | 31.11 Million USD | 7.61% |
| 2007 | 28.91 Million USD | 9.2% |
| 2006 | 26.48 Million USD | 160.3% |
| 2005 | 10.17 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 81.5 Million USD | -0.33% |
| 2024 Q2 | 78.51 Million USD | -3.67% |
| 2023 Q4 | 81.77 Million USD | -6.81% |
| 2023 Q3 | 87.75 Million USD | -1.82% |
| 2023 Q1 | 89.46 Million USD | -3.72% |
| 2023 Q2 | 89.37 Million USD | -0.1% |
| 2023 FY | 81.77 Million USD | -12.0% |
| 2022 FY | 92.92 Million USD | 10.02% |
| 2022 Q1 | 96.69 Million USD | 14.49% |
| 2022 Q2 | 92.51 Million USD | -4.32% |
| 2022 Q3 | 91.42 Million USD | -1.18% |
| 2022 Q4 | 92.92 Million USD | 1.64% |
| 2021 FY | 84.45 Million USD | -12.44% |
| 2021 Q2 | 88.85 Million USD | -4.82% |
| 2021 Q4 | 84.45 Million USD | -3.55% |
| 2021 Q1 | 93.34 Million USD | -3.23% |
| 2021 Q3 | 87.57 Million USD | -1.44% |
| 2020 Q3 | 96 Million USD | -1.55% |
| 2020 Q4 | 96.46 Million USD | 0.47% |
| 2020 FY | 96.46 Million USD | -7.73% |
| 2020 Q1 | 97.41 Million USD | -6.82% |
| 2020 Q2 | 97.52 Million USD | 0.11% |
| 2019 FY | 104.54 Million USD | -7.23% |
| 2019 Q4 | 104.54 Million USD | 0.75% |
| 2019 Q2 | 107.54 Million USD | -6.17% |
| 2019 Q3 | 103.76 Million USD | -3.52% |
| 2019 Q1 | 114.61 Million USD | 1.71% |
| 2018 FY | 112.69 Million USD | 20.87% |
| 2018 Q1 | 91.09 Million USD | -2.29% |
| 2018 Q3 | 87.43 Million USD | -3.33% |
| 2018 Q4 | 112.69 Million USD | 28.89% |
| 2018 Q2 | 90.44 Million USD | -0.71% |
| 2017 FY | 93.23 Million USD | -0.18% |
| 2017 Q2 | 87.8 Million USD | -4.42% |
| 2017 Q1 | 91.86 Million USD | -1.65% |
| 2017 Q4 | 93.23 Million USD | 3.19% |
| 2017 Q3 | 90.35 Million USD | 2.9% |
| 2016 Q1 | 89.2 Million USD | -2.95% |
| 2016 FY | 93.4 Million USD | 1.62% |
| 2016 Q3 | 91.07 Million USD | 3.62% |
| 2016 Q2 | 87.88 Million USD | -1.48% |
| 2016 Q4 | 93.4 Million USD | 2.56% |
| 2015 Q2 | 92.91 Million USD | 0.79% |
| 2015 FY | 91.91 Million USD | -3.65% |
| 2015 Q4 | 91.91 Million USD | -0.15% |
| 2015 Q3 | 92.05 Million USD | -0.92% |
| 2015 Q1 | 92.18 Million USD | -3.37% |
| 2014 Q2 | 93.46 Million USD | 2.59% |
| 2014 Q1 | 91.1 Million USD | 3.99% |
| 2014 Q3 | 93.9 Million USD | 0.47% |
| 2014 FY | 95.4 Million USD | 8.89% |
| 2014 Q4 | 95.4 Million USD | 1.6% |
| 2013 Q2 | 95.46 Million USD | -2.86% |
| 2013 Q3 | 91.91 Million USD | -3.72% |
| 2013 Q4 | 87.61 Million USD | -4.68% |
| 2013 FY | 87.61 Million USD | -11.14% |
| 2013 Q1 | 98.27 Million USD | -0.32% |
| 2012 Q3 | 96.93 Million USD | 1.63% |
| 2012 Q4 | 98.59 Million USD | 1.71% |
| 2012 FY | 98.59 Million USD | 3.22% |
| 2012 Q1 | 94.56 Million USD | -0.99% |
| 2012 Q2 | 95.38 Million USD | 0.86% |
| 2011 Q2 | 94.58 Million USD | 3.28% |
| 2011 Q4 | 95.51 Million USD | -0.58% |
| 2011 Q3 | 96.07 Million USD | 1.58% |
| 2011 FY | 95.51 Million USD | 3.76% |
| 2011 Q1 | 91.57 Million USD | -0.52% |
| 2010 FY | 92.05 Million USD | -11.25% |
| 2010 Q2 | 96.7 Million USD | -2.01% |
| 2010 Q1 | 98.68 Million USD | -4.85% |
| 2010 Q3 | 89.9 Million USD | -7.02% |
| 2010 Q4 | 92.05 Million USD | 2.38% |
| 2009 Q1 | 30.98 Million USD | -0.43% |
| 2009 Q3 | 101.65 Million USD | 204.84% |
| 2009 Q2 | 33.34 Million USD | 7.62% |
| 2009 Q4 | 103.72 Million USD | 2.03% |
| 2009 FY | 103.72 Million USD | 233.31% |
| 2008 Q4 | 31.11 Million USD | 2.46% |
| 2008 Q3 | 30.37 Million USD | 6.02% |
| 2008 Q1 | 30.63 Million USD | 5.92% |
| 2008 Q2 | 28.64 Million USD | -6.48% |
| 2008 FY | 31.11 Million USD | 7.61% |
| 2007 Q3 | 28.12 Million USD | 0.0% |
| 2007 FY | 28.91 Million USD | 9.2% |
| 2007 Q2 | 28.12 Million USD | 4.73% |
| 2007 Q1 | 26.85 Million USD | 1.41% |
| 2007 Q4 | 28.91 Million USD | 2.82% |
| 2006 Q4 | 26.48 Million USD | 0.0% |
| 2006 FY | 26.48 Million USD | 160.3% |
| 2005 FY | 10.17 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | -6.411% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 90.958% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -42.422% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 94.806% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -199.032% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -199.032% |
| SCYNEXIS, Inc. | 128.41 Million USD | 36.317% |
| Safety Shot Inc | 12.7 Million USD | -543.441% |
| Alpha Teknova, Inc. | 128.58 Million USD | 36.404% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 92.847% |
| Bright Green Corporation | 17.4 Million USD | -369.895% |
| Dynavax Technologies Corporation | 997.09 Million USD | 91.799% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 60.264% |
| Cosmos Health Inc. | 66.29 Million USD | -23.351% |
| PainReform Ltd. | 9.93 Million USD | -723.525% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -253.595% |
| Embecta Corp. | 1.21 Billion USD | 93.266% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 88.772% |
| Procaps Group, S.A. | 460.18 Million USD | 82.23% |
| Theratechnologies Inc. | 77.76 Million USD | -5.153% |
| Harrow Health, Inc. | 311.75 Million USD | 73.769% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -449.091% |
| Biofrontera Inc. | 27.93 Million USD | -192.768% |
| DURECT Corporation | 45.18 Million USD | -80.965% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 94.196% |
| Cronos Group Inc. | 1.13 Billion USD | 92.79% |
| OptiNose, Inc. | 107.72 Million USD | 24.091% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 82.64% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -46.162% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -254.821% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 82.224% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -586.146% |
| Radius Health, Inc. | 1.71 Billion USD | 95.234% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -53.463% |
| ProPhase Labs, Inc. | 91.92 Million USD | 11.042% |
| Phibro Animal Health Corporation | 982.18 Million USD | 91.674% |
| Procaps Group S.A. | 460.18 Million USD | 82.23% |
| Alvotech | 950.09 Million USD | 91.393% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -88.82% |
| Viatris Inc. | 47.68 Billion USD | 99.829% |
| Rockwell Medical, Inc. | 52.17 Million USD | -56.74% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 30.754% |
| SIGA Technologies, Inc. | 254.83 Million USD | 67.91% |
| Tilray Brands, Inc. | 4.33 Billion USD | 98.114% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 70.122% |
| Shineco, Inc. | 84.17 Million USD | 2.855% |
| PetIQ, Inc. | 868.22 Million USD | 90.581% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -869.116% |
| Incannex Healthcare Limited | 17.04 Million USD | -379.709% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 97.485% |
| Alimera Sciences, Inc. | 153.52 Million USD | 46.734% |
| Silver Spike Investment Corp. | 88.57 Million USD | 7.677% |
| Assertio Holdings, Inc. | 286.41 Million USD | 71.449% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -1273.987% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -141.971% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -161.742% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -517.293% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 68.683% |
| Hempacco Co., Inc. | 18.04 Million USD | -353.227% |
| Talphera, Inc. | 20.39 Million USD | -300.961% |
| Alvotech | 950.09 Million USD | 91.393% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 79.866% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 95.047% |
| Currenc Group, Inc. | 141.49 Million USD | 42.204% |
| Kamada Ltd. | 351.96 Million USD | 76.766% |
| Indivior PLC | 1.95 Billion USD | 95.809% |
| Evoke Pharma, Inc. | 7.06 Million USD | -1056.901% |
| Flora Growth Corp. | 23.62 Million USD | -246.127% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -517.293% |
| Evolus, Inc. | 188.99 Million USD | 56.732% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 93.61% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 94.595% |
| Akanda Corp. | 8.83 Million USD | -825.069% |